Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1

Preclinical and clinical studies have evidenced that effective targeted therapy treatment designed against receptor tyrosine kinases (RTKs) in different solid tumor paradigms is predicated on simultaneous inhibition of both the PI3K and MEK intracellular signaling pathways. Indeed, reactivation of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurupi, Richard, Floros, Konstantinos V., Jacob, Sheeba, Chawla, Ayesha T., Cai, Jinyang, Hu, Bin, Puchalapalli, Madhavi, Coon, Colin M., Khatri, Rishabh, Crowther, Giovanna Stein, Egan, Regina K., Murchie, Ellen, Greninger, Patricia, Dalton, Krista M., Ghotra, Maninderjit S., Boikos, Sosipatros A., Koblinski, Jennifer E., Harada, Hisashi, Sun, Yue, Morgan, Iain M., Basu, Devraj, Dozmorov, Mikhail G., Benes, Cyril H., Faber, Anthony C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728803/
https://www.ncbi.nlm.nih.gov/pubmed/36506869
http://dx.doi.org/10.1158/2767-9764.CRC-21-0137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728803/
https://www.ncbi.nlm.nih.gov/pubmed/36506869
http://dx.doi.org/10.1158/2767-9764.CRC-21-0137

Ejemplares similares